Lung cancer is the most lethal cancer type worldwide, with the majority of patients presenting with advanced stage disease. Targeting early stage disease pathogenesis would allow dramatic improvements in lung cancer patient survival. Recently, cell migration has been shown to be an integral process in early lung cancer ontogeny, with preinvasive lung cancer cells shown to migrate across normal epithelium prior to developing into invasive disease. TP53 mutations are the most abundant mutations in human nonsmall cell lung cancers and have been shown to increase cell migration via regulation of Rho-GTPase protein activity. In this review, we explore the possibility of targeting TP53-mediated Rho-GTPase activity in early lung cancer and the opportunities for translating this preclinical research into effective therapies for early stage lung cancer patients.
Bibliographical noteCopyright ©ERS 2017.
- Antineoplastic Agents/therapeutic use
- Biomarkers, Tumor/genetics
- Carcinoma, Non-Small-Cell Lung/drug therapy
- Cell Movement/drug effects
- Epithelial Cells/drug effects
- Lung Neoplasms/drug therapy
- Molecular Targeted Therapy
- Neoplasm Invasiveness
- Neoplasm Staging
- Signal Transduction/drug effects
- Tumor Suppressor Protein p53/genetics
- rho GTP-Binding Proteins/metabolism